An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Trial Profile

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational
  • Acronyms RIM-TD
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 17 Nov 2017 Planned End Date changed from 1 Sep 2019 to 8 Oct 2018.
    • 17 Nov 2017 Planned primary completion date changed from 1 Aug 2019 to 10 Sep 2018.
    • 08 Jun 2017 Interim results (n=304, Data cut off 30 Jun 2016) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top